HARBIN GLORIA PHARMACEUTICALS CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.18 CNY | -0.46% |
|
+1.87% | -13.15% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,155 | 6,660 | 7,034 | 6,397 | 5,583 | 5,517 |
| Enterprise Value (EV) 1 | 7,970 | 8,026 | 7,491 | 6,459 | 5,750 | 5,482 |
| P/E ratio | 48.9 x | -2.5 x | 17.6 x | 142 x | -19.2 x | 45.9 x |
| Yield | 0.43% | - | - | - | - | - |
| Capitalization / Revenue | 1.12 x | 1.32 x | 2.3 x | 2.03 x | 1.8 x | 2.1 x |
| EV / Revenue | 1.45 x | 1.59 x | 2.45 x | 2.05 x | 1.85 x | 2.09 x |
| EV / EBITDA | 11.6 x | 13.5 x | 4,078 x | 25.5 x | 26.8 x | 15.6 x |
| EV / FCF | 13.1 x | 60.8 x | 66.4 x | 24.8 x | 112 x | 31.6 x |
| FCF Yield | 7.62% | 1.65% | 1.51% | 4.03% | 0.89% | 3.17% |
| Price to Book | 1.42 x | 4.38 x | 3.81 x | 3.38 x | 3.42 x | 3.33 x |
| Nbr of stocks (in thousands) | 21,98,123 | 21,98,123 | 21,98,123 | 21,98,123 | 21,98,123 | 21,98,123 |
| Reference price 2 | 2.800 | 3.030 | 3.200 | 2.910 | 2.540 | 2.510 |
| Announcement Date | 23/04/19 | 27/04/20 | 28/04/21 | 25/04/22 | 23/04/23 | 12/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5,481 | 5,054 | 3,055 | 3,145 | 3,108 | 2,626 |
| EBITDA 1 | 684.9 | 595 | 1.837 | 253.2 | 214.5 | 350.5 |
| EBIT 1 | 503.3 | 416.3 | -144.7 | 115.7 | 85.61 | 246.1 |
| Operating Margin | 9.18% | 8.24% | -4.74% | 3.68% | 2.75% | 9.37% |
| Earnings before Tax (EBT) 1 | 178.9 | -2,604 | 565.1 | 85.97 | -269.7 | 176.8 |
| Net income 1 | 125.9 | -2,662 | 400 | 45.04 | -291.3 | 120.3 |
| Net margin | 2.3% | -52.67% | 13.1% | 1.43% | -9.37% | 4.58% |
| EPS 2 | 0.0573 | -1.211 | 0.1820 | 0.0205 | -0.1325 | 0.0547 |
| Free Cash Flow 1 | 607.1 | 132.1 | 112.8 | 260.4 | 51.24 | 173.7 |
| FCF margin | 11.08% | 2.61% | 3.69% | 8.28% | 1.65% | 6.61% |
| FCF Conversion (EBITDA) | 88.64% | 22.2% | 6,142.39% | 102.82% | 23.89% | 49.56% |
| FCF Conversion (Net income) | 482.21% | - | 28.2% | 578.03% | - | 144.34% |
| Dividend per Share 2 | 0.0120 | - | - | - | - | - |
| Announcement Date | 23/04/19 | 27/04/20 | 28/04/21 | 25/04/22 | 23/04/23 | 12/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1,815 | 1,366 | 457 | 62.4 | 167 | - |
| Net Cash position 1 | - | - | - | - | - | 35.6 |
| Leverage (Debt/EBITDA) | 2.65 x | 2.296 x | 248.8 x | 0.2465 x | 0.777 x | - |
| Free Cash Flow 1 | 607 | 132 | 113 | 260 | 51.2 | 174 |
| ROE (net income / shareholders' equity) | 2.98% | -88.8% | 23.2% | 2.75% | -15.7% | 7.54% |
| ROA (Net income/ Total Assets) | 3.39% | 3.28% | -1.66% | 1.57% | 1.22% | 4.26% |
| Assets 1 | 3,710 | -81,261 | -24,162 | 2,869 | -23,874 | 2,826 |
| Book Value Per Share 2 | 1.970 | 0.6900 | 0.8400 | 0.8600 | 0.7400 | 0.7500 |
| Cash Flow per Share 2 | 0.5900 | 0.6000 | 0.4100 | 0.6800 | 0.5600 | 0.3200 |
| Capex 1 | 104 | 48.4 | 43.7 | 34.5 | 33 | 29.6 |
| Capex / Sales | 1.9% | 0.96% | 1.43% | 1.1% | 1.06% | 1.13% |
| Announcement Date | 23/04/19 | 27/04/20 | 28/04/21 | 25/04/22 | 23/04/23 | 12/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.15% | 690M | |
| +20.32% | 43.95B | |
| +22.22% | 22.49B | |
| +11.68% | 14.71B | |
| +11.31% | 13.77B | |
| +42.32% | 12.3B | |
| -8.70% | 7.03B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.33% | 5.48B |
- Stock Market
- Equities
- 002437 Stock
- Financials Harbin Gloria Pharmaceuticals Co., Ltd